The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

Changes in the healthcare world are likely to limit opportunities for young researchers, especially women.Three leaders in ...